Krystal Biotech
30-Second Executive Brief
Executive Assessment
Krystal Biotech functions as a regional institution within Healthcare & Life Sciences, backed by 55% sourcing coverage, with accelerating strategic relevance.
- Maintains 2 mapped relationships across the graph
- 55% sourcing coverage across sourced relationships
- Tracked as regional institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Regional Institution
- Sourcing Coverage
- 55%
- Ecosystem Influence
- Moderate
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 2
- Technology Domains
- 4
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
A gene therapy company whose approved topical redosable gene therapy Vyjuvek, for dystrophic epidermolysis bullosa, generated $119.2 million in Q2 2026 revenue (up 24% year-over-year) and over $965.9 million cumulatively since launch. Krystal has secured more than 730 reimbursement approvals and expanded its US prescriber base past 640, with international momentum building in Germany, France, and Japan, and plans to launch in Spain and Italy later in 2026, backed by a $1.1 billion cash and investments position.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- GlobeNewswire — Krystal Biotech announces second quarter 2026 financial and operating resultscompany
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Krystal Biotech — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Krystal's 730+ reimbursement approvals is arguably the more important number than Vyjuvek's revenue growth rate
32% confidenceKrystal Biotech has secured more than 730 reimbursement approvals and expanded its US prescriber base past 640 for Vyjuvek, a rare-disease gene therapy, while generating $119.2 million in Q2 2026 revenue and planning launches in Spain and Italy.
This is InsightNodes' own interpretive read: for rare-disease gene therapies, the primary commercial bottleneck is typically not patient demand but the administrative process of securing payer reimbursement approval case-by-case -- reaching 730+ approvals and 640+ prescribers demonstrates Krystal has built a repeatable reimbursement-navigation capability rather than depending on ad hoc case-by-case wins, which is a more durable competitive asset for a single-product gene-therapy company than the revenue growth rate alone, and a template other rare-disease gene therapy companies (including Intellia, once lonvo-z is approved) will likely need to replicate.
InsightNodes analysis of Krystal Biotech Q2 2026 results · Aug 14, 2026
Krystal Biotech's Timeline
A sourced, dated history of Krystal Biotech's key moments — founding to present.
Aug 2026 · Q2 2026: Vyjuvek revenue reaches $119.2 million
Krystal Biotech reported Q2 2026 global Vyjuvek revenue of $119.2 million, up 24% year-over-year, with cumulative revenue since launch surpassing $965.9 million.
Aug 2026 · Plans Vyjuvek launches in Spain and Italy
Krystal Biotech announced plans to launch Vyjuvek in Spain and Italy later in 2026, extending its European commercial footprint beyond Germany and France.